- Highest-load omega-3 powder and formulation know-how now accessible to South American companies and consumers
- Strong market demand for dietary supplements in South America
- Next step in global roll-out of AvailOm® following recent registrations in Brazil and India
Essen, Germany. Evonik’s high-load omega-3 powder platform AvailOm® is now available in Argentina and Chile for the first time. Evonik has received approval from the regulatory authority INAL in Argentina for commercialization of AvailOm® 50 High EPA, AvailOm® 50 High DHA, and AvailOm® 50 High DHA Algae (vegan). Nutraceutical companies and consumers in Argentina and Chile can now benefit from a complete system solution that encompasses Evonik’s formulation know-how, its EUDRAGUARD® coatings for nutraceuticals, and the AvailOm® platform.
“We are proud to supply more nutraceutical companies in South America with our superior ingredient and global formulation capabilities. This latest approval is a next step to making AvailOm® available throughout this region and the world,” said Gilles Razzauti, director of Advanced Food Ingredients at Evonik’s Health Care business. Argentina is the next big important market for nutraceuticals in South America and the demand for omega-3 dietary supplements continues to grow strongly.
Omega-3 is a critical ingredient in formulations for dietary supplements tailored to healthy agers, pregnant women, and other consumer groups. AvailOm® is produced using Evonik’s proprietary process that combines omega-3 free fatty acids with the essential amino acid L-lysine. The complex formed is easy to process into a wide range of dosage forms with no fishy aftertaste.
AvailOm® has a bioavailability more than five times higher than traditional omega-3 fish oil soft-gel capsules. The powders are directly compressible into tablets and allow nutraceutical companies a wide range of opportunities to develop differentiated combination products with other active ingredients such as botanicals, vitamins, proteins and minerals for enhanced performance and synergistic benefits.
AvailOm® 50 High DHA is a supplement solution ideal for use during pregnancy and early motherhood and to support eye function or brain health in later stages of life. AvailOm® 50 High EPA promotes heart health, joint health and reduces inflammation. AvailOm® 50 High DHA Algae is for vegan or vegetarians and supports cognitive and eye health. All AvailOm® grades are produced from certified sustainable sources to protect marine ecosystems.
The AvailOm® platform is part of a nutraceuticals portfolio of advanced health ingredients, coatings, formulation services and finished dosage forms offered by Evonik’s Health Care business. As part of the life sciences division, Nutrition & Care, Evonik Health Care has centred its business on improving health and quality of life. The division is characterized by high growth prospects and above-average margin potential.
For more information on Evonik's AvailOm® platform please click here.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.